Phase IIb Protocol 011: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction in Treatment-Naive Patients Demonstrates Very Low HIV-1 RNA Levels in Patients With Wk 48 Protocol-Defined Virologic Failure

July 6-10, 2020; Virtual
Among 5 patients with protocol-defined virologic failure at Week 48 in this study, none experienced HIV-1 RNA > 200 copies/mL.
Format: Microsoft PowerPoint (.ppt)
File Size: 209 KB
Released: July 5, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

CCO commentary by Professor Don Smith on CROI 2021 data on ARV-associated weight gain and long-acting injectable ART

person default Don Smith, MD Released: April 20, 2021

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD
Released: April 9, 2021

CCO commentary by Daniel R. Kuritzkes, MD, on emerging HIV treatment option data presented at CROI 2021

Daniel R. Kuritzkes, MD Released: April 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue